It is associated with an EGFR inhibitor-resistant phenotype. Vandetanib, a dual inhibitor of VEGF and EGFR, has shown prolonged time to metastasis in CCA tumors that harbor both mutations. The gene discussed is VEGFA; the disease is cholangiocarcinoma.